Nebol (Nebivolol Hydrochloride)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which slows heart rate and reduces contractility. At the same time it stimulates endothelial nitric oxide synthase, increasing nitric oxide release and causing peripheral vasodilation, together lowering systemic vascular resistance and arterial pressure.

The appropriate dose of Nebol is determined by the prescribing healthcare professional based on the individual’s blood pressure, age, renal function and other clinical factors. Physicians typically start with a low dose and may adjust it to achieve target blood pressure, but exact dosing regimens should not be inferred without a prescription.

Safety of nebivolol during pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful evaluation.

To order Nebol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Nebivolol offers a unique combination of β1‑blockade and nitric‑oxide‑mediated vasodilation, which can provide better heart‑rate control and fewer metabolic side effects compared with non‑selective beta‑blockers. Compared with ACE inhibitors or calcium‑channel blockers, its mechanism is distinct, and choice of therapy depends on patient comorbidities, tolerance and physician preference.

Store Nebol below 25 °C in its original packaging, protecting it from moisture and direct light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Nebol is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably at the same time each day. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber.

Serious adverse events include severe bradycardia, heart block, acute hypotension, bronchospasm in patients with reactive airway disease, and allergic reactions such as rash or angioedema. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, difficulty breathing or signs of an allergic reaction.

Nebol should be avoided in patients with known hypersensitivity to nebivolol, severe bradycardia (heart rate < 45 bpm), second‑ or third‑degree atrioventricular block, cardiogenic shock, uncontrolled heart failure, or severe hepatic impairment. A thorough medical assessment is required before initiating therapy.